"The U.S. Food and Drug Administration today approved Clinolipid (lipid injectable emulsion, USP) for intravenous feeding (parenteral nutrition) in adult patients, providing a source of calories and essential fatty acids for adult patients who are"...
(Generic versions may still be available.)
- Clinician Information:
Aramine Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Aramine (metaraminol bitartrate) is a sympathomimetic amine used to prevent and treat the acute hypostensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. The brand name of this medication is discontinued, but generic versions may be available. Common side effects include sinus or ventricular tachycardia, or other arrhythmias.
The recommended dose of Aramine is 2 to 10 mg (0.2 to 1mL). Aramine may interact with digitalis, monoamine oxidase inhibitors (MAOIs), or tricyclic antidepressants. Tell your doctor all medications and supplements you use. During pregnancy, Aramine should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Aramine (metaraminol bitartrate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Aramine FDA Prescribing Information: Side Effects
Abscess formation, tissue necrosis, or sloughing rarely may follow the use of ARAMINE (metaraminol) . In choosing the site of injection, it is important to avoid those areas recognized as not suitable for use of any pressor agent and to discontinue the infusion immediately if infiltration or thrombosis occurs. Although the physician may be forced by the urgent nature of the patient's condition to choose injection sites that are not recognized as suitable, he should, when possible, use the preferred areas of injection. The larger veins of the antecubital fossa or the thigh are preferred to veins in the dorsum of the hand or ankle veins, particularly in patients with peripheral vascular disease, diabetes mellitus, Buerger's disease, or conditions with coexistent hypercoagulability.
Read the entire FDA prescribing information for Aramine (Metaraminol) »
Additional Aramine Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.